Absolute Quantification of [11C]docetaxel Kinetics in Lung Cancer Patients Using Positron Emission Tomography

Veldt, Astrid A.M. van der; Lubberink, Mark; Greuter, Henri N.; Comans, Emile F.I.; Herder, Gerarda J.M.; Yaqub, Maqsood; Schuit, Robert C.; Lingen, Arthur van; Rizvi, S. Nafees; Mooijer, Martien; Rijnders, Anneloes Y.; Windhorst, Albert D.; Smit, Egbert F.; Hendrikse, N. Harry; Lammertsma, Adriaan A.

doi:10.1158/1078-0432.ccr-10-2933

Cited by 20 publications

(30 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…11 C]DACA [119] , and [ 11 C]docetaxel [120,121] . Consequently, tumor perfusion may be predictive of tumor response to the above mentioned anticancer drugs.…”

Section: Tumor Perfusion and Drug Deliverymentioning

confidence: 99%

Positron emission tomography to assess hypoxia and perfusion in lung cancer

Verwer

Boellaard

Veldt

2014

WJCO

View full text Add to dashboard Cite

Core tip:This review provides an overview of the current applications of positron emission tomography for hypoxia and perfusion imaging in lung cancer. Available PET tracers are discussed and the benefits of combined hypoxia and perfusion PET imaging are clarified. Hypoxia imaging could aid in selecting patients for hypoxia-specific treatment strategies. To achieve this, consensus about the optimal imaging protocol and quantification method is essential. Large clinical trials are needed to confirm the value of hypoxia imaging for improving patient care.Verwer EE, Boellaard R, van der Veldt AAM. Positron emission tomography to assess hypoxia and perfusion in lung cancer.

show abstract

“…11 C]DACA [119] , and [ 11 C]docetaxel [120,121] . Consequently, tumor perfusion may be predictive of tumor response to the above mentioned anticancer drugs.…”

Section: Tumor Perfusion and Drug Deliverymentioning

confidence: 99%

Positron emission tomography to assess hypoxia and perfusion in lung cancer

Verwer

Boellaard

Veldt

2014

WJCO

View full text Add to dashboard Cite

show abstract

“…Furthermore, it was demonstrated that only less than 1% of the total infused dose of docetaxel accumulates in human tumors, indicating the need for strategies to enhance drug delivery to tumors. Finally and most importantly, it was shown that high tumor uptake of [ 11 C]docetaxel is related with improved tumor response in patients with lung cancer (24,31). Summarizing, these results indicate that […”

Section: Blood Kinetics Of [ 18 F]paclitaxel and [ 11 C]docetaxelmentioning

confidence: 80%

“…For both drugs, hepatobiliary excretion is the main pathway of elimination and a major fraction of the dose is excreted in feces as parent drug or metabolite. After intravenous injection in humans, both [ 18 F]paclitaxel and [ 11 C]docetaxel are cleared rapidly from blood (23,25,31) through the liver and gastrointestinal tract, whereas a minor component is excreted through the kidneys (23,25). Although it is known that radioactive metabolites can be formed from radiolabeled drugs (32) Although biodistribution studies are not primarily designed to measure tumor uptake, these studies provide information that may help to explain clinical observations such as efficacy and drug-related toxicities.…”

Section: Blood Kinetics Of [ 18 F]paclitaxel and [ 11 C]docetaxelmentioning

confidence: 99%

“…In addition, relatively high tracer uptake in the vertebral body makes it also unlikely that these tracers are useful for imaging bone metastases. Consequently, patients with metastatic prostate cancer are excluded, as these patients frequently present with metastatic sites in paraaortic lymph nodes, pelvic lymph nodes, and spine (50 (31) in breast cancer and lung cancer, respectively. This relatively low uptake in tumors is in line with the results obtained from biodistribution studies (23,25) and may be explained by the rapid clearance of the two tracers from blood (23,25,31).…”

Section: Blood Kinetics Of [ 18 F]paclitaxel and [ 11 C]docetaxelmentioning

confidence: 99%

See 1 more Smart Citation

In Vivo Imaging as a Pharmacodynamic Marker

Veldt

Lammertsma

2014

Clinical Cancer Research

Self Cite

View full text Add to dashboard Cite

Although numerous anticancer drugs are widely used in the clinic, many questions remain about pharmacokinetics, biodistribution, toxicities, and efficacy. Positron emission tomography (PET) using radiolabeled drugs is a promising method to further understand the clinical behavior of anticancer agents. In addition, it may contribute to better guided treatment planning in individual patients with cancer. Among the available anticancer drugs, considerable experience has been gained with radiolabeling taxanes. At present, two radiolabeled taxanes, paclitaxel and docetaxel, are available as PET tracers.

show abstract

“…PET has impacted drug discovery with earlier in vivo proof-of-target validation (8)(9)(10)(11)(12). For cancers and other diseases, hitting the target is associated with better efficacy, whereas missing the target results in greater toxicity.…”

mentioning

confidence: 99%